Core D - Genomics

核心 D - 基因组学

• 批准号: 10513939
• 负责人: Alexander L Greninger
• 金额: $ 284.12万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-16 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10513939
• 关键词: 2019-nCoV; Accreditation; Alleles; Animals; Antiviral Agents; Antiviral resistance; Binding Sites; Biochemical; Bioinformatics; Biological Assay; COVID-19 pandemic; Clinical Trials; Consensus; Country; DNA-Directed RNA Polymerase; Data; Development; Ensure; Enterovirus; Evolution; FDA Emergency Use Authorization; Family; Genbank; Gene Frequency; Genomics; Genotype; Herpesviridae; Human; In Vitro; Influenza A virus; Informatics; Infrastructure; Laboratories; Libraries; Measures; Metagenomics; Molecular; Mutate; Mutation; Nucleic Acids; Nucleotides; Oligonucleotides; Oral; Phase; Polymerase; Protocols documentation; Quality Control; RNA; RNA Viruses; Recovery; Reproducibility; Research Project Grants; Resistance; Resistance development; Resolution; SARS-CoV-2 genome; Scientific Inquiry; Sequence Read Archive; Shotguns; Specimen; Speed; Structure; Testing; Therapeutic Trials; Time; Universities; Vaccines; Variant; Viral; Viral Genome; Viral Load result; Viral Proteins; Virus; Visualization; Washington; Work; anti-viral efficacy; antiviral drug development; base; deep sequencing; experience; experimental study; genome sequencing; human coronavirus; in vivo; laboratory facility; longitudinal analysis; longitudinal design; medical countermeasure; molnupiravir; novel; pandemic disease; parainfluenza virus; phase III trial; preclinical study; protein complex; remdesivir; research clinical testing; resistance mechanism; resistance mutation; variant detection; variants of concern; viral genomics; virology; whole genome

Project Summary – Core D The ability of RNA viruses to rapidly mutate and develop resistance to medical countermeasures is a considerable barrier to the development of broadly acting antivirals. Viral genotyping can help determine the mechanistic basis and degree of barrier to the development of antiviral resistance. The Genomics Core will provide accurate, timely, and reproducible viral whole genome sequencing data for all Projects in the Antiviral Countermeasures Development Center (AC/DC). Dr. Alex Greninger, Core Leader, is Assistant Director at the UW Virology Lab and has over 15 years of experience in viral genomics and molecular testing. Using a combination of different sequencing approaches including metagenomic, hybridization capture, and amplicon tiling combined with a clinical trials-grade quality management infrastructure, our laboratory has built a robust and automated wet-lab and dry-lab pipeline for the recovery of RNA virus genomes. With the Center’s focus on developing and characterizing broadly acting RNA polymerase-directed antivirals against a variety of RNA viruses, the Genomics Core can simultaneously offer information on the mechanisms of resistance and activity of these antivirals using sequencing data as a readout. Specifically, we will recover viral whole genomes from viral isolates subjected to selection with the proposed antiviral compounds during in vitro and in vivo experiments to determine mechanisms of resistance and activity. In addition, the Genomics Core will enhance rigor, reproducibility, and generalizability of the proposed studies by ensuring the integrity of viral isolates and constructs prior to labor-intensive and expensive in vivo experimentation in all Projects. The Core ensures that the Research Projects can obtain accurate results from high-throughput genomics testing without redundant effort to enable scientific inquiry into the activity of antivirals against a variety of high consequence RNA viruses.

项目总结-核心D